Clinical trial
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory…
NCT00098761 · Pediatric Brain Tumor Consortium, Other · Completed
Key facts
| NCT number | NCT00098761 |
|---|---|
| Title | VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors |
| Official title | Phase I Study Of Cloretazine (VNP40101M) In Children With Recurrent, Progressive Or Refractory Primary Brain Tumors |
| Lead sponsor | Pediatric Brain Tumor Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | laromustine |
| Enrollment | 42 |
| Start date | Feb 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Feb 1, 2008 |
| First posted | Dec 9, 2004 |
| Last update posted | Jun 30, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: